A growing body of neuroimaging research is pinpointing exactly how psychedelic drugs hijack the brain’s visual system to produce vivid hallucinations, even when a person’s eyes are closed. Studies spanning LSD, psilocybin, DMT, and ayahuasca now converge on a shared mechanism: these substances loosen the brain’s normal sensory gatekeeping, flooding visual processing areas with internally generated signals that the brain treats as real. The findings carry direct implications for understanding consciousness itself and for the growing number of clinical trials testing psychedelics as treatments for depression and PTSD.
LSD Rewires the Visual Cortex in Real Time
The clearest early picture of what happens inside a hallucinating brain came from a multimodal neuroimaging study of LSD that combined fMRI, magnetoencephalography, and arterial spin labeling in the same participants. That research found three simultaneous changes in the visual system that tracked directly with how intense volunteers rated their hallucinations: increased blood flow in visual areas, decreased alpha-wave power in that same region, and expanded functional connectivity radiating outward from the primary visual area, known as V1. Alpha waves normally act as a brake on visual processing when no external stimulus is present. LSD appeared to release that brake, letting the visual cortex fire as though it were receiving input from the eyes when none existed.
The connectivity finding was especially striking. Under LSD, V1 began communicating with brain regions it does not normally talk to during rest, effectively recruiting distant networks into the act of generating imagery. This pattern offered a biological explanation for why LSD hallucinations feel so immersive: the brain’s visual hardware is not merely glitching but actively constructing scenes using the same circuitry it relies on for ordinary sight. As later work on how psychedelics can quiet rigid brain activity has emphasized, loosening entrenched patterns of communication appears to be a common theme across compounds, and in the case of LSD, it plays out vividly in the visual cortex.
Psilocybin Loosens the Brain’s Self-Inhibition
A more recent investigation published in Molecular Psychiatry used a double-blind, randomized, placebo-controlled, crossover design to examine psilocybin’s effects on eyes-closed visual imagery. The researchers applied dynamic causal modeling, a technique that estimates the direction and strength of signals flowing between brain regions, rather than just whether those regions are active at the same time. Their effective connectivity analysis mapped signal flow among four areas: the early visual cortex, the fusiform gyrus (involved in recognizing complex shapes and faces), the intraparietal sulcus (which helps orient spatial attention), and the inferior frontal gyrus (linked to cognitive control).
What they found was a pattern of altered self-inhibition in early visual areas under psilocybin. In plain terms, the visual cortex normally dampens its own activity when there is nothing to see. Psilocybin weakened that dampening, allowing internally generated signals to propagate up through higher visual and frontal regions. The result was vivid, dream-like imagery experienced with eyes shut. A separate behavioral and fMRI study tied psilocybin to changes in early visual computations by measuring how the drug altered participants’ susceptibility to the Ebbinghaus illusion, a classic perceptual test, and found correlations between V1 model parameters and subjective reports of geometric patterns. Together, these results suggest psilocybin does not simply add noise to visual processing but systematically shifts how the brain weighs internal predictions against external input, tipping perception toward what the brain expects or imagines rather than what the eyes deliver.
DMT and Ayahuasca Collapse Normal Brain Hierarchies
DMT, the active compound in the Amazonian brew ayahuasca, produces some of the most intense visual experiences reported by psychedelic users. A placebo-controlled study using simultaneous EEG and fMRI with intravenous DMT captured what happens at the network level during those experiences. The research documented global shifts in connectivity, including network disintegration, desegregation, and cortical gradient compression. That last term describes a flattening of the brain’s normal hierarchy, in which sensory areas at one end and abstract-thought regions at the other lose their usual separation. When that gradient compresses, the boundary between raw perception and memory-driven imagination effectively dissolves, helping explain why people describe DMT visions as both hyper-real and symbolically saturated.
Earlier fMRI work on ayahuasca had already hinted at this mechanism. That study found that the DMT-containing brew increased BOLD responses in the visual cortex during an imagery task performed with eyes closed, demonstrating that vivid visionary content can recruit visual brain areas even without any external visual input. Although ayahuasca also contains other plant compounds, the consistency between its effects and those of intravenous DMT strengthens the case that the key driver is serotonin 2A receptor activity shared by both preparations. When that receptor is strongly stimulated, higher-order association regions appear to exert less top-down control over sensory cortices, allowing bottom-up and internally generated signals to mingle in ways that feel like the sudden unveiling of an alternate reality rather than a simple distortion of the familiar world.
Shared Circuits With Neurological Disease
One of the more provocative lines of research connects psychedelic hallucinations to the visual disturbances seen in Lewy body dementia, a neurodegenerative condition that often produces vivid, unbidden visual experiences. A comparative analysis published in late 2025 found that both serotonergic psychedelics and Lewy body disorders produce distinct visual aberrations ranging from minor metamorphopsias to complex hallucinations of people and animals. The overlap is not coincidental: both conditions appear to involve disrupted inhibitory control in visual processing areas, though the triggers differ. In psychedelic states the disruption is temporary and chemically induced; in Lewy body disease it arises from progressive damage to neural circuits that ordinarily stabilize perception.
This parallel has two important consequences. First, it suggests that carefully controlled psychedelic experiments can serve as reversible models of pathological hallucinations, allowing researchers to probe which changes in connectivity and oscillatory dynamics are most tightly linked to specific visual symptoms. Second, it raises the possibility that some of the same interventions being explored to manage psychedelic experiences, such as manipulating sensory context or targeting particular receptor systems, might eventually inform treatments for distressing hallucinations in dementia. At the same time, the comparison underscores a key ethical distinction: where psychedelics temporarily relax the brain’s filters in a context people usually choose, neurodegenerative disease erodes those filters without consent, blurring the line between perception and imagination in ways that can be profoundly disorienting.
What Hallucinations Reveal About Conscious Vision
Taken together, the LSD, psilocybin, DMT, and ayahuasca findings converge on a unifying theme: the brain’s visual system is not a passive camera but an active prediction engine. Under ordinary conditions, higher cortical regions constantly generate models of what the world should look like and compare those models against incoming sensory data. Psychedelics appear to relax the precision of that comparison, either by reducing inhibitory rhythms in early visual cortex, weakening hierarchical boundaries between networks, or compressing large-scale gradients that normally keep perception and imagination distinct. When those constraints loosen, internally generated imagery can cascade through the same circuits that support everyday sight, which is why hallucinations can feel as compelling as anything seen with open eyes.
This mechanistic picture matters for more than curiosity about unusual states of consciousness. Clinical trials are increasingly testing whether the same neural flexibility that allows for psychedelic visuals can also help people break out of rigid patterns of thought associated with depression, addiction, and trauma. If visual hallucinations are one visible sign of a temporarily more plastic brain, then tracking changes in visual cortex activity and connectivity could become a useful biomarker for therapeutic response. At the same time, the overlap with hallucinations in conditions like Lewy body dementia is a reminder that loosening the brain’s filters is not inherently beneficial; context, intention, and support shape whether altered perception becomes a source of insight, distress, or both. As researchers refine dosing strategies and psychological frameworks around these substances, the visual system will remain a crucial window into how psychedelics reshape the most basic operations of conscious experience.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
